# Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A

> **NCT02280265** · NA · UNKNOWN · sponsor: **Nanjing Medical University** · enrollment: 15 (estimated)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Recombinant Human Coagulation Factor VIII for injection

## Key facts

- **NCT ID:** NCT02280265
- **Lead sponsor:** Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-11
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2014-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02280265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02280265, "Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02280265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*